JS

Jasbir Singh

Active Director Director DIN 10175090
DIN 10175090 First appointment May 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value •••• Premium profile

About Jasbir Singh

Data last updated:

Jasbir Singh is a Director at Flyvet Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Flyvet Pharmaceuticals Private Limited reported revenue of ₹7.1 Lakh (FY 2024).

DIN 10175090
Primary Designation Director
Industry Pharma
First Appointment 25 May 2023
Oldest Company Age 3 yrs
Largest company Flyvet Pharmaceuticals Private Limited · ₹7.1 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 May 20232023₹7.1 Lakh (FY 2024)Active

Board colleagues of Jasbir Singh

NameDINCompanyDesignation
Ajay10175091Flyvet Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Flyvet Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jasbir Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jasbir Singh

Jasbir Singh currently holds 1 directorship: Flyvet Pharmaceuticals Private Limited (Director, since 25 May 2023, revenue ₹7.1 Lakh (FY 2024)).

Jasbir Singh was first appointed on 25 May 2023 as Director at Flyvet Pharmaceuticals Private Limited.

The current boards of Jasbir Singh's companies include Ajay (Flyvet Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available